Crystal form of Afatinib dimaleate

The invention relates to a novel crystal form of Afatinib dimaleate, and a preparation method thereof. In an X-ray powder diffraction pattern of the novel crystal, peaks are observed at 2theta of 17.57, 22.52, 28.12, 32.19, 33.33, and 39.42 DEG; or peaks are observed at 2theta of 5.28, 12.27, 17.17, 21.22, 24.75, and 26.34 DEG. Crystal stability and powder flowingability of the novel crystal form are excellent; and the novel crystal form can be used for medicinal preparations.